strand-logoApollo Hospitals announced the launch of cutting-edge clinical genomic tests from the Strand Center for Genomics and Personalized Medicine, a part of Strand Life Sciences across its hospital network. These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo’s subsidiary, Sapien Biosciences in partnership with Strand Life Sciences. These tests, will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease & treatment course for better outcomes. Genomics is integral to Apollo’s focus on Research and Innovations. Genomic testing involves analyses of patient genomes – genes and sequences of DNA/RNA. The analysis helps create better prognostic tools for improved disease screening and prevention strategies. The patient benefits from optimized clinical care, personalization of treatment & monitoring of outcomes. These tests come with comprehensive pre- & post-test counselling to help the patient & their physicians to integrate the tests results into the clinical care provided. Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals says,“Apollo has always believed that personalized medicine is the future of healthcare delivery. Our Chairman, Dr. P.C Reddy’s foresight of personalized health is becoming a reality today with the availability of such cutting-edge genomic tests.”

Read Full Article